Search Results

You are looking at 21 - 30 of 817 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Amol K. Narang and Stephanie A. Terezakis

considered a standard regimen, with a higher number of chemotherapy cycles and/or radiation dose depending on number of risk factors, initial bulk, and response to treatment. Table 1 Definitions of Unfavorable Risk Factors by Specific Cooperative

Full access

Jerome Kim and Arti Hurria

such as diabetes mellitus are associated with an increased risk of mortality in older adults with cancer, 27 , 28 whereas organ dysfunction such as renal insufficiency is a risk factor for chemotherapy toxicity. 7 , 8 Medications: Close to one

Full access

Darren R. Feldman, Wendy L. Schaffer, and Richard M. Steingart

. 15 – 18 For example, higher rates of digital ischemia were identified in patients treated with cisplatin compared with those who were not (41% vs. 21%). 14 The cumulative dose of chemotherapy and the prevalence of conventional risk factors for

Full access

Matthew Ho, Maria Moscvin, Soon Khai Low, Sara Close, Robert Schlossman, Jacob Laubach, Brett Glotzbecker, Paul Richardson, and Giada Bianchi

to severe dehydration as defined by weight loss ≥ 5% body weight, suggesting OH could not be simply be explained by volume depletion. Multivariable analysis revealed three risk factors (white race, gabapentin, antihypertensives) and two protective

Full access

Rasha Abo El Hassan, Noura Anwar Abdel-Fatah, Hadeer Khalefa Ahmed, May Shawki, and Lamia El Wkeel

risk factors for Paclitaxel induced peripheral neuropathy (PIPN). Methods : NCT03492047 is prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m2 weekly for 12 weeks

Full access

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz, and Ghassan K. Abou-Alfa

's test was used to compare the cumulative incidence functions by covariates of interest including age, sex, race, treatment era, HCC etiologic risk factor, Child-Pugh score, AFP level, and median calcium and ALP levels. Among patients who presented with

Full access

Craig H. Moskowitz, Andrew Zelenetz, and Heiko Schoder

stages II, III, or IV disease and 1 to 3 risk factors according to age-adjusted International Prognostic Index score. After induction therapy with 4 cycles of R-CHOP-14, all patients underwent FDG-PET. Patients who had negative FDG-PET results then

Full access

Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald, and Andrea B. McKee

(NLST) entry criteria. 1 – 4 All 3 organizations have expanded their screening recommendations to include older patients, younger patients, and/or patients with additional risk factors for lung cancer. Inclusion of these additional populations has

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

recurrence rates. In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. Methods Literature Search Strategy The authors searched the Cochrane Controlled Trials Register (CENTRAL

Full access

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

-intent resection of CLM, it is critical to explore this issue further and develop a potential surveillance algorithm specific to this patient cohort. Within this context, the primary aim of this study was to assess the changes in recurrence risks and risk factors